News

PMLive31m
FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type
The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...
PMLive33m
J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis
Johnson & Johnson (J&J) and Protagonist Therapeutics’ investigational oral peptide icotrokinra (JNJ-2113) has been associated ...
PMLive34m
GSK shares promising phase 3 results for linerixibat in PBC-related itch
The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...